Medtronic self-expanding TAVR shows durability benefit over surgery at 5 years, analysis shows

The rate of structural valve deterioration at five years with open heart surgery (SAVR) was 4.38% versus 2.57% in patients undergoing Medtronic's supra-annular, self-expanding transcatheter aortic valve replacement (TAVR), according to a pooled analysis that was presented on Monday at the American College of Cardiology's Scientific Sessions.